Nanotechnological Drug Delivery Strategies in Epilepsy
Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected worldwide. Although there are a wide range of drugs approved for epilepsy, 30% of the patients do not...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | otro |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/370565 |
| Acceso en línea: | http://hdl.handle.net/10261/370565 https://api.elsevier.com/content/abstract/scopus_id/85206428084 |
| Access Level: | acceso abierto |
| Palabra clave: | Nanomedicine Blood-brain barrier Drug delivery Epilepsy Nanocarriers http://metadata.un.org/sdg/3 Ensure healthy lives and promote well-being for all at all ages |
| Sumario: | Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected worldwide. Although there are a wide range of drugs approved for epilepsy, 30% of the patients do not respond to these treatments. In this context, nanomedicine constitutes a promising alternative to enhance the central nervous system bioavailability of antiepileptic drugs. The encapsulation of different active compounds in nanocarriers gives rise to enhanced effectiveness mainly due to their targeting and penetration into the deepest brain regions as well as the protection of the encapsulated drug. Thus, in this chapter we explore the recent advances in the development of different controlled drug delivery systems for the management of epilepsy disorders. |
|---|